Anticancer Efficacy Services

Since its founding in 1941, Southern Research has evaluated approximately half of all FDA-approved anticancer drugs currently on the market for patients. Our cancer therapeutics professionals have evaluated hundreds of compounds each year to establish the in vitro and in vivo efficacy of potential anticancer drugs. Our experience with numerous commercial and government clients, including the National Cancer Institute, enables us to design optimal studies that provide critical preclinical anticancer efficacy data for our clients' drug development programs and regulatory applications. Southern Research has evaluated standard chemotherapeutic agents against multiple human xenograft models and has performed preclinical efficacy studies with in vitro model systems and immune-compromised and immune-competent rodents.


In vitro laboratories

• Efficacy testing using a range of in vitro assays
• Genetically characterized 12-panel cell line screen
• 3D cell culture model efficacy screening
• NCI-60 cell line panel testing
• More than 200 human tumor cell lines available for evaluation
• Combination studies including radiosensitization
• Rapid screening systems for drug testing in real time


In vivo laboratories

• More than 50 human xenograft models
• Syngeneic tumor models including immuno-oncology
• Nine genetically matched tumor models from the 12-panel cell line screen
• Combination studies including radiosensitization
• Efficacy database of clinical agents


Key Capabilities

• Genetically characterized cell lines
• 3D cell culture models
• xCELLigence Real-Time Cell Analyzer for label-free assays
• Cell-cycle analysis
• Apoptosis measurements
• Colony formation assays
• Invasion and migration assays
• Angiogenesis assays
• Custom assay and method development
• Transient or continuous treatment protocols for in vitro and in vivo studies
• Irradiation capabilities for in vitro and in vivo studies
• Combination cytotoxicity studies including radiosensitization
• Sequencing and scheduling for in vitro and in vivo studies
• Protein and gene expression
• Large capacity for nude, SCID, and immunocompetent mice
• Direct contact with the principal scientists



How To Work With Us

As a CRO service provider, Southern Research’s Drug Development division has a straightforward business model. Contact our business development representative by clicking here. A confidentiality disclosure agreement will be initiated (your agreement or ours) to facilitate detailed discussions around your specific needs. One of our subject matter experts will be brought into the discussion to ensure we have a comprehensive understanding of your project. A proposal will then be prepared, outlining the tasks to be accomplished, along with a budget and timeline. Upon acceptance of the proposal, a contract will be provided to establish the legal framework for the project.